Dominant epitope peptide of Ebola virus envelope glycoprotein as well as coding gene and application thereof
A technology of Ebola virus and envelope glycoprotein, which is applied in the field of dominant epitope peptide of Ebola virus envelope glycoprotein, and achieves the effect of wide application prospect and safe and convenient use
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0022] Obtaining the dominant epitope peptide of Ebola virus envelope glycoprotein
[0023] Step1: Amino acid sequence search:
[0024] The glycoprotein of Zaire Ebola virus (GP, accession number: AY354458.1) was obtained from the NCBI GenBank database as input for various bioinformatics tools for epitope prediction, conservation analysis, molecular docking and experiments .
[0025] Step2: Epitope prediction:
[0026] For H2-Db, H2-Dd, H2-Kb, H2-Kd, H2-Kk and H2-Ld epitope prediction, web-based tools such as the IEDB method are recommended (http: / / tools.iedb.org / mhci / ), SMMPMBEC from the immune epitope database (http: / / tools.immunepitope.org / mhci / ), NetMHCpan 4.1 (http: / / www.cbs.dtu.dk / services / NetMHCpan / ), SYFPEITHI (http: / / www.syfpeit hi.de / bin / MHCServer.dll / EpitopePrediction.htm) and Rankpep (http: / / imed.med.ucm.es / Tools / rankpep.html) for prediction. Predicted epitopes that accounted for the top 2% of total predicted epitopes were selected. Finally, epitopes predict...
Embodiment 2
[0051] Application of dominant epitope peptide of Ebola virus envelope glycoprotein
[0052] The invention lays a foundation for the research of the new EBOV genetic engineering vaccine through the prediction of the dominant MHC class I epitope peptide on the EBOV GP, various computer analyzes and ELISpot test verification.
[0053] After the above experimental research, it is found that the dominant MHC class I epitope peptide on EBOV GP can effectively stimulate the body's cellular immune response.
[0054] In recent years, although vaccines related to EBOV have been developed at home and abroad, from the perspective of application, there are still many shortcomings in this type of vaccine, the most important of which is that the cellular immune response stimulated by the body is not good enough, and there are certain defects. security risks. If the EBOV GP dominant MHC class I epitope peptide screened out by the method of the present invention is used to stimulate the body...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com